Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of FT522, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy with Alloimmune Defense Receptor (ADR) in Relapsed/Refractory B-Cell Lymphoma

Veronika Bachanova, Abhinav Deol, Taha Mahdi Salih Al-Juhaishi, Premal D. Lulla, Michael T. Byrne, Carol Wong, Cara Bickers, Trever Greene, Lilly Wong, Bertha Villa, Deepa Patel, Bahram Bob Valamehr, Rebecca Elstrom, Matthew Lunning

Blood (2024) 144 (Supplement 1): 6543.

https://doi.org/10.1182/blood-2024-198684

Published: 2024

Journal Articles

Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

Amitkumar Mehta, Umar Farooq, Andy Chen, Joseph P. McGuirk, Thomas Ly, Lilly Wong, Sarah Cooley, Bahram Valamehr, Rebecca Elstrom, Yu-Waye Chu, Jae H. Park

Blood (2022) 140 (Supplement 1): 4577–4578.

https://doi.org/10.1182/blood-2022-167194

Published: 2022

Journal Articles

Phase I Study of FT516, an Off-the-Shelf iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma

Krish Patel, Veronika Bachanova, Aaron M Goodman, John M. Pagel, Kelly Griffis, Marlisa Anderson, Siminder Atwal, Cara Bickers, Peter Szabo, Lilly Wong, Yu-Waye Chu, Rebecca Elstrom, Paolo Strati

Blood (2021) 138 (Supplement 1): 3873.

https://doi.org/10.1182/blood-2021-151520

Published: 2021

Journal Articles

Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Veronika Bachanova, Armin Ghobadi, Krish Patel, Jae H Park, Ian W. Flinn, Prutha Shah, Carol Wong, Cara Bickers, Peter Szabo, Lilly Wong, Bahram Valamehr, Siminder Atwal, Yu-Waye Chu, Rebecca Elstrom, Paolo Strati

Blood (2021) 138 (Supplement 1): 823.

https://doi.org/10.1182/blood-2021-151185

Published: 2021

Journal Articles

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Blood (2019) 134 (11): 851–859.

https://doi.org/10.1182/blood.2019001160

Published: 2019

Includes: Supplemental data

Journal Articles

Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study

Yuqin Song, MD PhD, Quanli Gao, MD, Huilai Zhang, PhD, Lei Fan, MD PhD, Jianfeng Zhou, PhD, Dehui Zou, MD, Wei Li, MD, Haiyan Yang, PhD, Ting Liu, MD, Quanshun Wang, MD PhD, Fangfang Lv, MD, Yu Yang, MD, Haiyi Guo, MD, Liudi Yang, MD, Rebecca Elstrom, MD, Jane Huang, MD, William Novotny, MD, Vivian Wei, PhD, Jun Zhu, MD PhD

Blood (2018) 132 (Supplement 1): 682.

https://doi.org/10.1182/blood-2018-99-117848

Published: 2018

Journal Articles

A Phase I Study of the Anti-CD79b THIOMAB TM -Drug Conjugate DCDS0780A in Patients (pts) with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Alex F. Herrera, MD, Manish R Patel, MD, John M. Burke, MD, Ranjana H. Advani, MD, Bruce D. Cheson, MD, Jeffrey P. Sharman, MD, Elicia Penuel, Andrew G. Polson, PhD, Ning Leng, PhD, Chunze Li, PhD, Eva Schuth, PhD, Anjali Vaze, PhD, Divya Samineni, PhD, Rebecca Elstrom, MDMA, Catherine S Diefenbach

Blood (2017) 130 (Supplement 1): 4129.

https://doi.org/10.1182/blood.V130.Suppl_1.4129.4129

Published: 2017

Journal Articles

Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma

Andrew D. Zelenetz, MD PhD, Gilles A. Salles, Kylie D Mason, MBBS, FRACP, FRCPA, PhD, Carla Casulo, MD, Steven Le Gouill, MD PhD, Laurie H Sehn, MD, Hervé Tilly, MD PhD, Guillaume Cartron, MD PhD, Martine ED Chamuleau, MD, Andre Goy, MD, Constantine S. Tam, MD, Pieternella J Lugtenburg, MD PhD, Rebecca Elstrom, MD, Thalia Farazi, MD PhD, Juan Liu, Edith Szafer-Glusman, PhD, Mehrdad Mobasher, MD, Franck Morschhauser

Blood (2016) 128 (22): 3032.

https://doi.org/10.1182/blood.V128.22.3032.3032

Published: 2016

Journal Articles

Monotherapy with Subcutaneous (SC) Injections of Low Doses of Humanized Anti-CD20 Veltuzumab Is Active in Chronic Lymphocytic Leukemia (CLL)

Matt Kalaycio, MD, O George Negrea, MD, Rebecca Elstrom, MD, Charles Farber, MD, PhD, Heather Horne, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 192.

https://doi.org/10.1182/blood.V120.21.192.192

Published: 2012

Journal Articles

Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results

Michael B Tomblyn, MD, MS, Thomas E. Witzig, MD, Andrew L Himelstein, MD, Rebecca Elstrom, MD, Ebenezer A Kio, MD, Robert M Sharkey, PhD, Jonathan Rojo, MD, William Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 3680.

https://doi.org/10.1182/blood.V120.21.3680.3680

Published: 2012

Journal Articles

Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population

Anthony R Mato, MD, Andre Goy, MD, Kathryn Waksmundzki, BS, Tatyana Feldman, MD, Tania Zielonka, RDC, Ewelina A Protomastro, BA, Coleen Bejot, MSN, NP-C, Gabriella Gadaleta, RN, APN-C, Scott D Rowley, MD, Michele L Donato, MD, Andrew L Pecora, MD, Katherine Facchin, RN, John P. Leonard, MD, Richard R. Furman, MD, Jia Ruan, MD, PhD, Tsiporah B Shore, Usama Gergis, MD, Morton Coleman, MD, Rebecca Elstrom, MD

Blood (2012) 120 (21): 4269.

https://doi.org/10.1182/blood.V120.21.4269.4269

Published: 2012

Journal Articles

Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues

Thomas Clozel, MD, ShaoNing Yang, Ms, Matthias Kormaksson, PhD, Rebecca Elstrom, MD, Aparna Vasanthakumar, BSc, MSc, PhD, Sarah Brennan, PhD, Biljana Culjkovic, PhD, Michael Leser, Peter Martin, MD, Katherine LB Borden, PhD, Y. Lynn Wang, MD, PhD, Shuhua Cheng, PhD, Wayne Tam, MD, PhD, Rita Shaknovich, MD/PhD, Amy Chadburn, MD, Lucy Godley, MD, PhD, John P. Leonard, MD, Ari Melnick, MD, Leandro Cerchietti, MD

Blood (2011) 118 (21): 1617.

https://doi.org/10.1182/blood.V118.21.1617.1617

Published: 2011

Journal Articles

Patients with Limited Stage Extranodal Marginal Zone Lymphoma Have Excellent Overall Survival Regardless of Choice of Therapy Type or Observation

Sarah C. Rutherford, MD, Wayne Tam, MD, PhD, Richard R. Furman, MD, Rebecca Elstrom, MD, Jia Ruan, MD, PhD, Morton Coleman, MD, John P. Leonard, MD, Peter Martin, MD

Blood (2011) 118 (21): 1579.

https://doi.org/10.1182/blood.V118.21.1579.1579

Published: 2011

Journal Articles

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Beata Holkova, MD, Edward B. Perkins, MD, PhD, Lubomir Sokol, MD, PhD, Kristy L. Richards, PhD, MD, Samir Parekh, MD, Rebecca Elstrom, MD, Ashraf Z. Badros, MD, Igor Espinoza-Delgado, MD, Michael J. Schell, PhD, Amy Kimball, MD, PhD, Mary Beth Tombes, RN, Ellen Shrader, Heidi Sankala, PhD, Domenico Coppola, MD, Maciej Kmieciak, PhD, Daniel Sullivan, MD, John D. Roberts, MD, Steven Grant, MD

Blood (2011) 118 (21): 779.

https://doi.org/10.1182/blood.V118.21.779.779

Published: 2011

Journal Articles

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy,

Rebecca Elstrom, MD, John P. Leonard, MD, Stanley J. Goldsmith, Paul Christos, Peter Martin, Joseph Osborne, Daniel Lebovic, MD, Ramsey Abdallah, CRC, June Greenberg, Richard R. Furman, MD, Jia Ruan, MD, PhD, Kent A. Griffith, Morton Coleman, MD, Mark S. Kaminski, MD

Blood (2011) 118 (21): 3712.

https://doi.org/10.1182/blood.V118.21.3712.3712

Published: 2011

Journal Articles

Standard Dose Rituximab Plus 2–4 Cycles of Pulse Dexamethasone Is Effective and Tolerable in Treatment of Immune Thrombocytopenia (ITP)

Rebecca Elstrom, MD, Waleed Ghanima, Soo Y Lee, Ithamar Turenne, James B Bussel, MD

Blood (2011) 118 (21): 1166.

https://doi.org/10.1182/blood.V118.21.1166.1166

Published: 2011

Journal Articles

Autologous Stem Cell Transplantation Is Feasible and of Potential Benefit In Very Elderly Patients with Lymphoma and Limited Comorbidities

Rebecca Elstrom, MD, Peter Martin, FRCPC, MD, MS, Tsiporah B. Shore, MD, Richard R. Furman, MD, Jia Ruan, MD, PhD, Tomer M Mark, MD, MSc, Roger N Pearse, MD, PhD, Morton Coleman, MD, John P. Leonard, MD, Usama Gergis, MD

Blood (2010) 116 (21): 3561.

https://doi.org/10.1182/blood.V116.21.3561.3561

Published: 2010

Journal Articles

Fludarabine Plus I-131 Tositumomab as Initial Treatment for Follicular Lymphoma: Half of Patients In Remission at Over 10 Years Median Followup.

Peter Martin, FRCPC, MD, MS, Morton Coleman, MD, Richard R. Furman, MD, Shankar Vallabhajosula, Dong Sun Kim, Andrew Edelstein, Julia Morrison, Rebecca Elstrom, MD, Jia Ruan, MD, PhD, Stanley J. Goldsmith, John P. Leonard, MD

Blood (2010) 116 (21): 1785.

https://doi.org/10.1182/blood.V116.21.1785.1785

Published: 2010

Journal Articles

Rituximab Plus Three Cycles of Dexamethasone In the Treatment of Immune Thrombocytopenia (ITP): a Pilot Study.

Rebecca Elstrom, MD, Soo Y. Lee, BS, James B. Bussel, MD

Blood (2010) 116 (21): 3697.

https://doi.org/10.1182/blood.V116.21.3697.3697

Published: 2010

Journal Articles

CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL).

Jia Ruan, MD, PhD, Peter Martin, Richard R Furman, MD, Julie M. Vose, MD, Ann LaCasce, MD, Ying-Kuen K. Cheung, PhD, Jennifer O'Loughlin, Rebecca Elstrom, MD, Ruben Niesvizky, MD, Amy Chadburn, MD, Scott Ely, MD, Ethel Cesarman, MD, Morton Coleman, MD, John P. Leonard, MD

Blood (2009) 114 (22): 2682.

https://doi.org/10.1182/blood.V114.22.2682.2682

Published: 2009

NARROW

Safety and Efficacy of FT522, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy with Alloimmune Defense Receptor (ADR) in Relapsed/Refractory B-Cell Lymphoma

Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

Phase I Study of FT516, an Off-the-Shelf iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma

Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study

A Phase I Study of the Anti-CD79b THIOMAB TM -Drug Conjugate DCDS0780A in Patients (pts) with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma

Monotherapy with Subcutaneous (SC) Injections of Low Doses of Humanized Anti-CD20 Veltuzumab Is Active in Chronic Lymphocytic Leukemia (CLL)

Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results

Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population

Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues

Patients with Limited Stage Extranodal Marginal Zone Lymphoma Have Excellent Overall Survival Regardless of Choice of Therapy Type or Observation

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy,

Standard Dose Rituximab Plus 2–4 Cycles of Pulse Dexamethasone Is Effective and Tolerable in Treatment of Immune Thrombocytopenia (ITP)

Autologous Stem Cell Transplantation Is Feasible and of Potential Benefit In Very Elderly Patients with Lymphoma and Limited Comorbidities

Fludarabine Plus I-131 Tositumomab as Initial Treatment for Follicular Lymphoma: Half of Patients In Remission at Over 10 Years Median Followup.

Rituximab Plus Three Cycles of Dexamethasone In the Treatment of Immune Thrombocytopenia (ITP): a Pilot Study.

CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only